BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sayiner M, Golabi P, Stepanova M, Younossi I, Nader F, Racila A, Younossi ZM. Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use. Hepatology 2019;69:237-44. [PMID: 30015376 DOI: 10.1002/hep.30174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Shahab O, Sayiner M, Paik J, Felix S, Golabi P, Younossi ZM. Burden of Primary Biliary Cholangitis Among Inpatient Population in the United States. Hepatol Commun 2019;3:356-64. [PMID: 30859148 DOI: 10.1002/hep4.1314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Lee BT, Tana MM, Kahn JA, Dara L. We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases. Hepatology 2021;74:2876-87. [PMID: 34056734 DOI: 10.1002/hep.31985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bogdanowska-Charkiewicz D, Rogalski P, Janica J, Rogalska-Plonska M, Aleksiejuk E, Antonowicz S, Dabrowski A, Daniluk J. Minimal hepatic encephalopathy may be present despite the absence of non-invasive and elastography evidence of cirrhosis in patients with primary biliary cholangitis. Adv Med Sci 2021;66:293-301. [PMID: 34192643 DOI: 10.1016/j.advms.2021.06.001] [Reference Citation Analysis]
4 Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut 2021;70:1989-2003. [PMID: 34266966 DOI: 10.1136/gutjnl-2020-322362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
5 Gordon SC, Wu KH, Lindor K, Bowlus CL, Rodriguez CV, Anderson H, Boscarino JA, Trudeau S, Rupp LB, Haller IV, Romanelli RJ, Vanwormer JJ, Schmidt MA, Daida YG, Sahota A, Vincent J, Zhang T, Li J, Lu M; for the FOLD Investigators. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. Am J Gastroenterol 2020;115:262-70. [DOI: 10.14309/ajg.0000000000000512] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Chen CJ, Cheng JS, Wang HE, Huang CW, Hu JH, Chen WT, Chang MY, Ku HP, Lin CY, Chien RN, Chang ML. Identification of the Representative Primary Biliary Cholangitis Cohort in Taiwan: A Comparison of Four Nationwide Cohorts. J Clin Med 2021;10:2226. [PMID: 34063859 DOI: 10.3390/jcm10112226] [Reference Citation Analysis]
7 John BV, Aitcheson G, Schwartz KB, Khakoo NS, Dahman B, Deng Y, Goldberg D, Martin P, Taddei TH, Levy C, Kaplan DE. Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis. Hepatology 2021;74:879-91. [PMID: 33636012 DOI: 10.1002/hep.31776] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
8 Sayiner M, Stepanova M, De Avila L, Golabi P, Racila A, Younossi ZM. Outcomes of Liver Transplant Candidates with Primary Biliary Cholangitis: The Data from the Scientific Registry of Transplant Recipients. Dig Dis Sci 2020;65:416-22. [PMID: 31451982 DOI: 10.1007/s10620-019-05786-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Invernizzi F, Cilla M, Trapani S, Guarino M, Cossiga V, Gambato M, Morelli MC, Morisco F, Burra P, Floreani A. Gender and Autoimmune Liver Diseases: Relevant Aspects in Clinical Practice. JPM 2022;12:925. [DOI: 10.3390/jpm12060925] [Reference Citation Analysis]
10 Galoosian A, Hanlon C, Tana M, Cheung R, Wong RJ. Race/Ethnicity and Insurance-Specific Disparities in In-Hospital Mortality Among Adults with Primary Biliary Cholangitis: Analysis of 2007–2014 National Inpatient Sample. Dig Dis Sci 2020;65:406-15. [DOI: 10.1007/s10620-019-05809-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Younossi ZM, Golabi P, Henry L. A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. Journal of Clinical Gastroenterology 2019;53:331-41. [DOI: 10.1097/mcg.0000000000001179] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
12 Shen H, Ding L, Baig M, Tian J, Wang Y, Huang W. Improving glucose and lipids metabolism: drug development based on bile acid related targets. Cell Stress 2021;5:1-18. [PMID: 33447732 DOI: 10.15698/cst2021.01.239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Sahu R, Mishra R, Majee C. An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance. Expert Review of Gastroenterology & Hepatology 2020;14:985-98. [DOI: 10.1080/17474124.2020.1797485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cançado GGL, Braga MH, Ferraz MLG, Villela-Nogueira CA, Terrabuio DRB, Cançado ELR, Nardelli MJ, Faria LC, Gomes NMF, de Oliveira EMG, Rotman V, de Oliveira MB, da Cunha SMCF, Mazo DFC, Mendes LSC, Ivantes CAP, Codes L, de Almeida E Borges VF, Pace FHL, Pessoa MG, Signorelli IV, Coral GP, Bittencourt PL, Levy C, Couto CA; Members of the Brazilian Cholestasis Study Group Consortium. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. Ann Hepatol 2021;27:100546. [PMID: 34600142 DOI: 10.1016/j.aohep.2021.100546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]